Skip to main content
. 2017 Sep 29;8:1221. doi: 10.3389/fimmu.2017.01221

Figure 2.

Figure 2

CAL-101-primed pmel-1 CD8+ T cells exert robust antitumor response against B16F10 tumors. (A) Frequency of donor pmel-1 T cells and extracellular markers on pmel-1 (vβ13+) donor T cells in tumor 7 days following treatment; n = 3 mice/group. One-way repeated measures ANOVA; ns, not statistically significant, *p < 0.05. Tumor burden (mm2) of (B) individual mice and (C) Average tumor burden (mm2) of treatment groups which received no T cell treatment, or 8 × 105 pmel-1 CD8+ T cells primed with vehicle, AKTi, or CAL-101 ex vivo; n = 10–12 mice/group in one experiment. (D) Percent survival of above treatment groups. Kaplan–Meier curve analyzed by log rank test; ****p < 0.0001 (see also Figure S1 in Supplementary Material).